Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526226 | 1.00 | KCNJ1 (0.44) | KCNJ1ALDH1A1SIRT6MAPK1P4HA1 | |
| SCHEMBL13165465 | 0.87 | KCNJ1 (0.52) | KCNJ1ALDH1A1SIRT6MAPK1P4HA1 | |
| SCHEMBL29957141 | 0.78 | KDM4E (0.48) | ALDH1A1SIRT6MAPK1P4HA1MIF | |
| SCHEMBL15305157 | 0.78 | KDM4E (0.48) | KCNJ1ALDH1A1SIRT6MAPK1P4HA1 | |
| SCHEMBL241781 | 0.78 | KDM4E (0.48) | ALDH1A1SIRT6MAPK1P4HA1MIF | |
| SCHEMBL5041030 | 0.76 | SIRT6 (0.59) | KCNJ1ALDH1A1SIRT6P4HA1MIF | |
| SCHEMBL16664325 | 0.76 | SIRT6 (0.39) | ALDH1A1SIRT6P4HA1MIFP4HTM | |
| SCHEMBL21477593 | 0.76 | KCNJ1 (0.44) | KCNJ1ALDH1A1SIRT6MAPK1P4HA1 | |
| SCHEMBL30091932 | 0.76 | POLB (0.50) | KCNJ1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL3608091 | 0.76 | KCNJ1 (0.44) | KCNJ1ALDH1A1SIRT6MAPK1P4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-116600657-A | Application of naringenin in improving quality of phlorizin taste | 西姆莱斯有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-08-25 | — | — | US | disclosed |
| EP-3983406-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2022-04-20 | — | — | EP | disclosed |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015048507-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225342-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | KCNJ1 2839/4885ALDH1A1 3757/4885SIRT6 3786/4885 |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | KCNJ1 93/4885ALDH1A1 707/4885SIRT6 760/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | KCNJ1 2839/4885ALDH1A1 3757/4885SIRT6 3786/4885 |
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | AADAC, ACSL3, ACSL1 | KCNJ1 897/4885ALDH1A1 304/4885SIRT6 1350/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | KCNJ1 355/4885ALDH1A1 902/4885SIRT6 885/4885 |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | KCNJ1 2839/4885ALDH1A1 3757/4885SIRT6 3786/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | KCNJ1 2839/4885ALDH1A1 3757/4885SIRT6 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.